WASHINGTON (January 21, 2021)
The Personalized Medicine Coalition (PMC) today applauds the selection of Janet Woodcock, M.D., as Interim Commissioner of the U.S. Food and Drug Administration. A dedicated public servant with an unparalleled commitment to personalized medicine, Dr. Woodcock will help ensure that patients and health systems continue to benefit from the efficient regulatory oversight of innovative tests and treatments that, when fully developed, have the ability to transform the delivery of health care by aligning prevention and treatment plans in keeping with each patient’s biological characteristics, circumstances, and values.
Dr. Woodcock’s enthusiasm for and longstanding commitment to personalized medicine is second to none. PMC presented her its First Annual Award for Leadership in Personalized Medicine in 2005 when there were fewer than five personalized medicines on the market in the United States. During her tenure as the Director of FDA’s Center for Drug Evaluation and Research, the number of FDA-approved personalized medicines has grown from five in 2008 to 286 in 2020 based in no small part on her vision for the future of drug development and patient care. According to PMC’s annual analyses of new drug approvals, personalized medicines have accounted for more than 25 percent of newly approved drugs each of the last six years.
“With more than three decades of experience at FDA and a commitment to approving safer and more efficacious medicines that address unmet patient needs, Janet Woodcock is well-positioned to lead FDA at this critical moment in the agency’s history,” said PMC President Edward Abrahams.